Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDe La Rue Regulatory News (DLAR)

Share Price Information for De La Rue (DLAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 95.20
Bid: 95.20
Ask: 96.80
Change: -1.00 (-1.04%)
Spread: 1.60 (1.681%)
Open: 93.40
High: 95.40
Low: 93.40
Prev. Close: 96.20
DLAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to revised proposal

24 Jan 2011 09:10

RNS Number : 9461Z
De La Rue PLC
24 January 2011
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

24 January 2011

 

 

FOR IMMEDIATE RELEASE

 

De La Rue PLC ("De La Rue" or the "Company")

Rejection of revised proposal from François-Charles Oberthur Fiduciaire S.A. ("Oberthur")

 

The Board of De La Rue (the "Board") announces that it has received this weekend an oral indication from Oberthur that it is prepared to increase its indicative proposal for the Company to a price of 935 pence per De La Rue share.

 

The Board, which is being advised by Rothschild and J.P. Morgan Cazenove, has considered this revised proposal carefully and believes that it continues to undervalue significantly the strong fundamentals of the Company and its long term prospects. Accordingly, the Board has unanimously rejected this revised proposal and informed Oberthur that it does not intend to pursue this latest approach.

 

This announcement is being made without the consent of Oberthur and accordingly there can be no certainty any offer will be forthcoming or as to the terms of any offer.

 

Nicholas Brookes, Chairman of De La Rue, said:

 

"The Board has carefully considered Oberthur's revised proposal and believes that it continues to significantly undervalue the Company and its prospects. The Board therefore unanimously rejected this latest approach. With the recent appointment of Tim Cobbold to lead a restructured and strengthened management team, the Board is confident that De La Rue has a promising future as an independent company."

 

Tim Cobbold, Chief Executive of De La Rue, said:

 

"My first few weeks at De La Rue have confirmed my view that De La Rue is a high quality business with substantial potential in growing markets. There are, of course, opportunities for improvement, building on changes already made, but shareholders should be in no doubt of my absolute commitment to realise De La Rue's full potential and deliver significant value."

 

 

Enquiries:

 

De La Rue

Nicholas Brookes (Chairman)

Tim Cobbold (Chief Executive)

Colin Child (Group Finance Director)

 

01256 605000

Brunswick

Jon Coles

Kate Holgate

 

020 7404 5959

Rothschild

Crispin Wright

Neil Thwaites

 

020 7280 5000

J.P. Morgan Cazenove

Michael Wentworth-Stanley

Alex Garner

020 7588 2828

 

 

A copy of this announcement will be available at www.delarue.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

NM Rothschild & Sons Limited ("Rothschild"), which is authorised and regulated by the Financial Services Authority, is acting exclusively as independent financial adviser to De La Rue and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than De La Rue for providing the protections afforded to clients of Rothschild or for providing advice in relation to this matter, the content of this announcement or any matter referred to herein. Neither Rothschild nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Rothschild in connection with this announcement, any statement contained herein or otherwise.

 

J.P. Morgan plc, which conducts its UK investment banking business as J.P. Morgan Cazenove and is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively as independent financial adviser to De La Rue and no one else in connection with the subject matter of this announcement and will not be responsible to any other person for providing the protections afforded to its clients nor for providing advice in relation to the subject matter referred to in this announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RSPUSRKRAKAAURR
Date   Source Headline
30th May 20247:00 amRNSStrategic Update
2nd May 202411:39 amRNSHolding(s) in Company
17th Apr 20247:00 amRNSPre-Close Trading Statement
16th Apr 202411:52 amRNSHolding(s) in Company
16th Apr 202410:59 amRNSHolding(s) in Company
3rd Apr 20247:00 amRNSExtension of contract with Microsoft
2nd Apr 202411:25 amRNSTotal Voting Rights
7th Mar 20241:04 pmRNS2023 AGM Voting Update
23rd Feb 20242:06 pmRNSAdditional Listing
29th Jan 20244:14 pmRNSHolding(s) in Company
26th Jan 20244:38 pmRNSDirector/PDMR Shareholding
18th Jan 20243:19 pmRNSHolding(s) in Company
18th Jan 202412:13 pmRNSHolding(s) in Company
2nd Jan 202411:33 amRNSBlock listing Interim Review
21st Dec 20233:51 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNS2023/24 half year results
27th Nov 20232:53 pmRNSHolding(s) in Company
1st Nov 20231:51 pmRNSTotal Voting Rights
30th Oct 202311:05 amRNSHolding(s) in Company
13th Oct 202310:27 amRNSDirector/PDMR Shareholding
6th Oct 20237:00 amRNSPre-close Trading Statement
2nd Oct 202311:47 amRNSTotal Voting Rights
20th Sep 202312:59 pmRNSDirector/PDMR Shareholding
13th Sep 20231:09 pmRNSHolding(s) in Company
7th Sep 20231:59 pmRNSResult of AGM
7th Sep 20237:00 amRNSAGM statement and trading update
4th Sep 202312:36 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
14th Aug 20233:30 pmRNSHolding(s) in Company
11th Aug 20232:58 pmRNSHolding(s) in Company
11th Aug 20237:00 amRNSDirectorate Change
4th Aug 20237:00 amRNSDirectorate Change
3rd Aug 20239:21 amRNSAppointment of Joint Broker
2nd Aug 20233:26 pmRNSDirector/PDMR Shareholding
1st Aug 20239:00 amRNSTotal Voting Rights
28th Jul 20231:44 pmRNSDirector/PDMR Shareholding
24th Jul 20233:04 pmRNSHolding(s) in Company
20th Jul 20234:03 pmRNSHolding(s) in Company
20th Jul 202312:17 pmRNSAnnual Financial Report
19th Jul 20231:01 pmRNSHolding(s) in Company
11th Jul 202310:28 amRNSDirector/PDMR Shareholding
4th Jul 202312:59 pmRNSHolding(s) in Company
3rd Jul 20235:44 pmRNSHolding(s) in Company
3rd Jul 202312:12 pmRNSBlock listing Interim Review
3rd Jul 202312:09 pmRNSTotal Voting Rights
30th Jun 20231:40 pmRNSHolding(s) in Company
30th Jun 20231:35 pmRNSHolding(s) in Company
30th Jun 202310:11 amRNSDirector/PDMR Shareholding
29th Jun 20237:00 amRNSFY23 full year results
28th Jun 20235:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.